TLR4/PKC-mediated tight junction modulation: A clinical marker of chemotherapy-induced gut toxicity?

International Journal of Cancer

Volumn 135, Issue 11, 2014, Pages 2483-2492

  Wardill, Hannah R ^a   Gibson, Rachel J ^a   Logan, Richard M ^a   Bowen, Joanne M ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Chemotherapy; Mucositis; Protein kinase C; Tight junctions; Toll like receptor 4

Indexed keywords

CLAUDIN; GAMMA INTERFERON; INTERLEUKIN 1BETA; JUNCTIONAL ADHESION MOLECULE; JUNCTIONAL ADHESION MOLECULE A; MEMBRANE PROTEIN; MYELOID DIFFERENTIATION FACTOR 88; OCCLUDIN; PROTEIN KINASE C; PROTEIN ZO1; PROTEIN ZO2; PROTEIN ZO3; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; TLR4 PROTEIN, HUMAN;

CELL DISRUPTION; CHEMOTHERAPY INDUCED GUT TOXICITY; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; GASTROINTESTINAL MUCOSA; GASTROINTESTINAL TOXICITY; GENE DISRUPTION; HOMEOSTASIS; HUMAN; INNATE IMMUNITY; INTESTINE MUCOSA PERMEABILITY; MICROBIOME; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; TIGHT JUNCTION; CHEMICALLY INDUCED; GASTROINTESTINAL DISEASE; METABOLISM;

ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; GASTROINTESTINAL DISEASES; HUMANS; PROTEIN KINASE C; SIGNAL TRANSDUCTION; TIGHT JUNCTIONS; TOLL-LIKE RECEPTOR 4;

EID: 84921648735     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28656     Document Type: Review

References (123)

1. Keefe DM. Supportive care silos: time to forge cross-links, using mucositis as an example. Curr Opin Support Palliat Care 2007;1:40-2.
2. Gutheil J, Kearns C. The chemotherapy source book, 2nd edn. Baltimore: Williams and Wilkins, 1997. 1518.
3. Sonis ST, Elting LS, Keefe D, et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 2004;100: 1995-2025.
4. Al-Dasooqi N, Sonis ST, Bowen JM, et al. Emerging evidence on the pathobiology of mucositis. Support Care Cancer 2013;21:2075-83.
5. Bowen JM, Elad S, Hutchins RD, et al. Methodology for the MASCC/ISOO mucositis clinical practice guidelines update. Support Care Cancer 2013;21:303-8.
6. Gibson RJ, Keefe DM, Lalla RV, et al. Systematic review of agents for the management of gastrointestinal mucositis in cancer patients. Support Care Cancer 2013;21:313-26.
7. Abd El-Atti S, Wasicek K, Mark S, et al. Use of probiotics in the management of chemotherapyinduced diarrhea: a case study. JPEN J Parenter Enteral Nutr 2009;33:569-70.
8. Bowen JM, Stringer AM, Gibson RJ, et al. VSL#3 probiotic treatment reduces chemotherapy-induced diarrhea and weight loss. Cancer Biol Ther 2007;6:1449-54.
9. Blijlevens N, de Chateau M, Krivan G, et al. In a high-dose melphalan setting, palifermin compared with placebo had no effect on oral muco-sitis or related patient's burden. Bone Marrow Transplant 2013;48:966-71.
10. Goldberg JD, Zheng J, Castro-Malaspina H, et al. Palifermin is efficacious in recipients of TBI-based but not chemotherapy-based allogeneic hematopoietic stem cell transplants. Bone Marrow Transplant 2013;48:99-104.
11. Zhou WJ, Geng ZH, Spence JR, et al. Induction of intestinal stem cells by R-spondin 1 and Slit2 augments chemoradioprotection. Nature 2013; 501:107-11.
12. Gibson RJ, Bowen JM. Biomarkers of regimenrelated mucosal injury. Cancer Treat Rev 2011; 37:487-93.
13. Spielberger R, Stiff P, Bensinger W, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2004;351: 2590-8.
14. Sonis ST. Oral mucositis in cancer therapy. J Support Oncol 2004;2:3-8.
15. Sonis ST. A biological approach to mucositis. J Support Oncol 2004;2:21-32; discussion 5-6.
16. Sonis ST. The pathobiology of mucositis. Nat Rev Cancer 2004;4:277-84.
17. Keefe DM, Brealey J, Goland GJ, et al. Chemotherapy for cancer causes apoptosis that precedes hypoplasia in crypts of the small intestine in humans. Gut 2000;47:632-7.
18. Stringer AM, Gibson RJ, Bowen JM, et al. Irinotecan-induced mucositis manifesting as diarrhoea corresponds with an amended intestinal flora and mucin profile. Int J Exp Pathol 2009; 90:489-99.
19. Stringer AM, Gibson RJ, Logan RM, et al. Chemotherapy-induced diarrhea is associated with changes in the luminal environment in the DA rat. Exp Biol Med (Maywood) 2007;232:96-106.
20. Al-Dasooqi N, Bowen JM, Gibson RJ, et al. Irinotecan-induced alterations in intestinal cell kinetics and extracellular matrix component expression in the dark agouti rat. Int J Exp Pathol 2011;92:357-65.
21. Al-Dasooqi N, Sonis ST, Bowen JM, et al. Emerging evidence on the pathobiology of mucositis. Support Care Cancer 2013.
22. Wardill HR, Bowen JM, Gibson RJ. Chemotherapy-induced gut toxicity: are alterations to intestinal tight junctions pivotal? Cancer Chemother Pharmacol 2012;70:627-35.
23. Anderson JM, Balda MS, Fanning AS. The structure and regulation of tight junctions. Curr Opin Cell Biol 1993;5:772-8.
24. Wardill HR, Bowen JM, Gibson RJ. Irinotecan disrupts tight junction protein occludin in the rat small intestine. Support Care Cancer 2013.
25. Hamada K, Shitara Y, Sekine S, et al. Zonula Occludens-1 alterations and enhanced intestinal permeability in methotrexate-treated rats. Cancer Chemother Pharmacol 2010;66:1031-8.
26. Youmba SB, Belmonte L, Galas L, et al. Methotrexate modulates tight junctions through NFkappaB, MEK and JNK Pathways. J Pediatr Gastroenterol Nutr 2011.
27. Hamada K, Kakigawa N, Sekine S, et al. Disruption of ZO-1/claudin-4 interaction in relation to inflammatory responses in methotrexateinduced intestinal mucositis. Cancer Chemother Pharmacol 2013.
28. Nakao T, Kurita N, Komatsu M, et al. Irinotecan injures tight junction and causes bacterial translocation in rat. J Surg Res 2012;173:341-7.
29. Umesaki Y, Setoyama H. Structure of the intestinal flora responsible for development of the gut immune system in a rodent model. Microbes Infect 2000;2:1343-51.
30. Li X, Wang C, Nie J, et al. Toll-like receptor 4 increases intestinal permeability through upregulation of membrane PKC activity in alcoholic steatohepatitis. Alcohol 2013.
31. Mitic LL, Van Itallie CM, Anderson JM. Molecular physiology and pathophysiology of tight junctions I. Tight junction structure and function: lessons from mutant animals and proteins. Am J Physiol Gastrointest Liver Physiol 2000; 279:G250-4.
32. Gonzalez-Mariscal L, Tapia R, Chamorro D. Crosstalk of tight junction components with signaling pathways. Biochim Biophys Acta 2008; 1778:729-56.
33. McCarthy KM, Skare IB, Stankewich MC, et al. Occludin is a functional component of the tight junction. J Cell Sci 1996;109 (Part 9):2287-98.
34. Ulluwishewa D, Anderson RC, McNabb WC, et al. Regulation of tight junction permeability by intestinal bacteria and dietary components. J Nutr 2011;141:769-76.
35. Schulzke JD, Gitter AH, Mankertz J, et al. Epithelial transport and barrier function in occludin-deficient mice. Biochim Biophys Acta 2005;1669:34-42.
36. Bertiaux-Vandaele N, Youmba SB, Belmonte L, et al. The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype. Am J Gastroenterol 2011;106:2165-73.
37. Furuse M, Hata M, Furuse K, et al. Claudinbased tight junctions are crucial for the mammalian epidermal barrier: a lesson from claudin-1-deficient mice. J Cell Biol 2002;156:1099-111.
38. Balda MS, Gonzalez-Mariscal L, Matter K, et al. Assembly of the tight junction: the role of diacylglycerol. J Cell Biol 1993;123:293-302.
39. Mandell KJ, Parkos CA. The JAM family of proteins. Adv Drug Deliv Rev 2005;57:857-67.
40. Iden S, Misselwitz S, Peddibhotla SS, et al. aPKC phosphorylates JAM-A at Ser285 to promote cell contact maturation and tight junction formation. J Cell Biol 2012;196:623-39.
41. Tsukita S, Katsuno T, Yamazaki Y, et al. Roles of ZO-1 and ZO-2 in establishment of the beltlike adherens and tight junctions with paracellular permselective barrier function. Ann N Y Acad Sci 2009;1165:44-52.
42. Umeda K, Ikenouchi J, Katahira-Tayama S, et al. ZO-1 and ZO-2 independently determine where claudins are polymerized in tight-junction strand formation. Cell 2006;126:741-54.
43. Keefe DM, Cummins AG, Dale BM, et al. Effect of high-dose chemotherapy on intestinal permeability in humans. Clin Sci (Lond) 1997;92:385-9.
44. Melichar B, Dvorak J, Hyspler R, et al. Intestinal permeability in the assessment of intestinal toxicity of cytotoxic agents. Chemotherapy 2005;51: 336-8.
45. Melichar B, Kohout P, Bratova M, et al. Intestinal permeability in patients with chemotherapyinduced stomatitis. J Cancer Res Clin Oncol 2001;127:314-8.
46. Blijlevens NM, Donnelly JP, de Pauw BE. Prospective evaluation of gut mucosal barrier injury following various myeloablative regimens for haematopoietic stem cell transplant. Bone Marrow Transplant 2005;35:707-11.
47. Wardill HR, Bowen JM. Chemotherapy-induced mucosal barrier dysfunction: an updated review on the role of intestinal tight junctions. Curr Opin Support Palliat Care 2013.
48. Clarke H, Soler AP, Mullin JM. Protein kinase C activation leads to dephosphorylation of occludin and tight junction permeability increase in LLC-PK1 epithelial cell sheets. J Cell Sci 2000;113 (Part 18):3187-96.
49. Clarke H, Marano CW, Peralta Soler A, et al. Modification of tight junction function by protein kinase C isoforms. Adv Drug Deliv Rev 2000;41:283-301.
50. Forster C. Tight junctions and the modulation of barrier function in disease. Histochem Cell Biol 2008;130:55-70.
51. Cummins PM. Occludin: one protein, many forms. Mol Cell Biol 2012;32:242-50.
52. Fish SM, Proujansky R, Reenstra WW. Synergistic effects of interferon gamma and tumour necrosis factor alpha on T84 cell function. Gut 1999;45:191-8.
53. Wang F, Graham WV, Wang Y, Witkowski ED, Schwarz BT, Turner JR. Interferon-gamma and tumor necrosis factor-alpha synergize to induce intestinal epithelial barrier dysfunction by upregulating myosin light chain kinase expression. Am J Pathol 2005;166:409-19.
54. Capaldo CT, Nusrat A. Cytokine regulation of tight junctions. Biochim Biophys Acta 2009;1788: 864-71.
55. Burgel N, Bojarski C, Mankertz J, et al. Mechanisms of diarrhea in collagenous colitis. Gastroenterology 2002;123:433-43.
56. Schulzke JD, Ploeger S, Amasheh M, et al. Epithelial tight junctions in intestinal inflammation. Ann N Y Acad Sci 2009;1165:294-300.
57. Schmitz H, Barmeyer C, Fromm M, et al. Altered tight junction structure contributes to the impaired epithelial barrier function in ulcerative colitis. Gastroenterology 1999;116:301-9.
58. Barmeyer C, Harren M, Schmitz H, et al. Mechanisms of diarrhea in the interleukin-2-deficient mouse model of colonic inflammation. Am J Physiol Gastrointest Liver Physiol 2004;286: G244-52.
59. Ma TY, Boivin MA, Ye D, et al. Mechanism of TNF-{alpha} modulation of Caco-2 intestinal epithelial tight junction barrier: role of myosin light-chain kinase protein expression. Am J Physiol Gastrointest Liver Physiol 2005;288: G422-30.
60. Ma TY, Iwamoto GK, Hoa NT, et al. TNFalpha-induced increase in intestinal epithelial tight junction permeability requires NF-kappa B activation. Am J Physiol Gastrointest Liver Physiol 2004;286:G367-76.
61. Al-Sadi R, Ye D, Dokladny K, Ma TY. Mechanism of IL-1beta-induced increase in intestinal epithelial tight junction permeability. J Immunol 2008;180:5653-61.
62. Ley RE, Peterson DA, Gordon JI. Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell 2006;124:837-48.
63. Spitz J, Yuhan R, Koutsouris A, et al. Enteropathogenic Escherichia coli adherence to intestinal epithelial monolayers diminishes barrier function. Am J Physiol 1995;268:G374-9.
64. Groschwitz KR, Hogan SP. Intestinal barrier function: molecular regulation and disease pathogenesis. J Allergy Clin Immunol 2009;124: 3-20; quiz 1-2.
65. Berkes J, Viswanathan VK, Savkovic SD, et al. Intestinal epithelial responses to enteric pathogens: effects on the tight junction barrier, ion transport, and inflammation. Gut 2003;52: 439-51.
66. Philpott DJ, McKay DM, Sherman PM, et al. Infection of T84 cells with enteropathogenic Escherichia coli alters barrier and transport functions. Am J Physiol 1996;270:G634-45.
67. Muza-Moons MM, Schneeberger EE, Hecht GA. Enteropathogenic Escherichia coli infection leads to appearance of aberrant tight junctions strands in the lateral membrane of intestinal epithelial cells. Cell Microbiol 2004;6:783-93.
68. Singh U, Van Itallie CM, Mitic LL, et al. CaCo-2 cells treated with Clostridium perfringens enterotoxin form multiple large complex species, one of which contains the tight junction protein occludin. J Biol Chem 2000;275:18407-17.
69. Ahrne S, Hagslatt ML. Effect of lactobacilli on paracellular permeability in the gut. Nutrients 2011;3:104-17.
70. Ewaschuk JB, Diaz H, Meddings L, et al. Secreted bioactive factors from Bifidobacterium infantis enhance epithelial cell barrier function. Am J Physiol Gastrointest Liver Physiol 2008; 295:G1025-34.
71. Madsen K, Cornish A, Soper P, et al. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 2001;121:580-91.
72. Ukena SN, Singh A, Dringenberg U, et al. Probiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity. PLoS One 2007;2:e1308.
73. Al-Dasooqi N, Gibson RJ, Bowen JM, et al. Matrix metalloproteinases are possible mediators for the development of alimentary tract mucositis in the dark agouti rat. Exp Biol Med (Maywood) 2010;235:1244-56.
74. Clark IM, Swingler TE, Sampieri CL, et al. The regulation of matrix metalloproteinases and their inhibitors. Int J Biochem Cell Biol 2008;40: 1362-78.
75. Wolf M, Albrecht S, Marki C. Proteolytic processing of chemokines: implications in physiological and pathological conditions. Int J Biochem Cell Biol 2008;40:1185-98.
76. Manicone AM, McGuire JK. Matrix metalloproteinases as modulators of inflammation. Semin Cell Dev Biol 2008;19:34-41.
77. Gorodeski GI. Estrogen decrease in tight junctional resistance involves matrixmetalloproteinase-7-mediated remodeling of occludin. Endocrinology 2007;148:218-31.
78. Siu MK, Lee WM, Cheng CY. The interplay of collagen IV, tumor necrosis factor-alpha, gelatinase B (matrix metalloprotease-9), and tissue inhibitor of metalloproteases-1 in the basal lamina regulates Sertoli cell-tight junction dynamics in the rat testis. Endocrinology 2003;144:371-87.
79. Vermeer PD, Denker J, Estin M, et al. MMP9 modulates tight junction integrity and cell viability in human airway epithelia. Am J Physiol Lung Cell Mol Physiol 2009;296:L751-62.
80. Jeong S, Ledee DR, Gordon GM, et al. Interaction of clusterin and matrix metalloproteinase-9 and its implication for epithelial homeostasis and inflammation. Am J Pathol 2012;180:2028-39.
81. Al-Alem LF, McCord LA, Southard RC, et al. Activation of the PKC pathway stimulates ovarian cancer cell proliferation, migration, and expression of MMP7 and MMP10. Biol Reprod 2013.
82. Rigor RR, Beard RS, Jr., Litovka OP, et al. Interleukin-1beta-induced barrier dysfunction is signaled through PKC-theta in human brain microvascular endothelium. Am J Physiol Cell Physiol 2012;302:C1513-22.
83. Terres AM, Pajares JM, Hopkins AM, et al. Helicobacter pylori disrupts epithelial barrier function in a process inhibited by protein kinase C activators. Infect Immun 1998;66:2943-50.
84. Cario E, Gerken G, Podolsky DK. Toll-like receptor 2 controls mucosal inflammation by regulating epithelial barrier function. Gastroenterology 2007;132:1359-74.
85. Cario E, Gerken G, Podolsky DK. Toll-like receptor 2 enhances ZO-1-associated intestinal epithelial barrier integrity via protein kinase C. Gastroenterology 2004;127:224-38.
86. Eckert JJ, McCallum A, Mears A, et al. Relative contribution of cell contact pattern, specific PKC isoforms and gap junctional communication in tight junction assembly in the mouse early embryo. Dev Biol 2005;288:234-47.
87. Eckert JJ, McCallum A, Mears A, et al. Specific PKC isoforms regulate blastocoel formation during mouse preimplantation development. Dev Biol 2004;274:384-401.
88. Helfrich I, Schmitz A, Zigrino P, et al. Role of aPKC isoforms and their binding partners Par3 and Par6 in epidermal barrier formation. J Invest Dermatol 2007;127:782-91.
89. Denisenko N, Burighel P, Citi S. Different effects of protein kinase inhibitors on the localization of junctional proteins at cell-cell contact sites. J Cell Sci 1994;107 (Part 4):969-81.
90. Chen ML, Pothoulakis C, LaMont JT. Protein kinase C signaling regulates ZO-1 translocation and increased paracellular flux of T84 colonocytes exposed to Clostridium difficile toxin A. J Biol Chem 2002;277:4247-54.
91. Farhadi A, Keshavarzian A, Ranjbaran Z, et al. The role of protein kinase C isoforms in modulating injury and repair of the intestinal barrier. J Pharmacol Exp Ther 2006;316:1-7.
92. Fasano A, Fiorentini C, Donelli G, et al. Zonula occludens toxin modulates tight junctions through protein kinase C-dependent actin reorganization, in vitro. J Clin Invest 1995;96:710-20.
93. Nozawa Y, Nishihara K, Akizawa Y, et al. Protein kinase C activation by Helicobacter pylori in human gastric epithelial cells limits interleukin-8 production through suppression of extracellular signal-regulated kinase. J Pharmacol Sci 2004;94:233-9.
94. Suzuki T, Elias BC, Seth A, et al. PKC eta regulates occludin phosphorylation and epithelial tight junction integrity. Proc Natl Acad Sci USA 2009;106:61-6.
95. Andreeva AY, Krause E, Muller EC, et al. Protein kinase C regulates the phosphorylation and cellular localization of occludin. J Biol Chem 2001;276:38480-6.
96. Andreeva AY, Piontek J, Blasig IE, et al. Assembly of tight junction is regulated by the antagonism of conventional and novel protein kinase C isoforms. Int J Biochem Cell Biol 2006;38:222-33.
97. Yoshida K, Kanaoka S, Takai T, et al. EGF rapidly translocates tight junction proteins from the cytoplasm to the cell-cell contact via protein kinase C activation in TMK-1 gastric cancer cells. Exp Cell Res 2005;309:397-409.
98. Schmitt M, Horbach A, Kubitz R, et al. Disruption of hepatocellular tight junctions by vascular endothelial growth factor (VEGF): a novel mechanism for tumor invasion. J Hepatol 2004; 41:274-83.
99. Coyne CB, Vanhook MK, Gambling TM, et al. Regulation of airway tight junctions by proinflammatory cytokines. Mol Biol Cell 2002;13: 3218-34.
100. Logan RM, Stringer AM, Bowen JM, et al. Serum levels of NFkappaB and proinflammatory cytokines following administration of mucotoxic drugs. Cancer Biol Ther 2008;7: 1139-45.
101. Bowen JM, Coller JK, Hutchinson MR, et al. Expression of TLRs in the rat intestine following chemotherapy for cancer. Brain Behav Immun 2012;26.
102. Guney Y, Ozel Turkcu U, Hicsonmez A, et al. Ghrelin may reduce radiation-induced mucositis and anorexia in head-neck cancer. Med Hypotheses 2007;68:538-40.
103. Kawai T, Akira S. TLR signaling. Semin Immunol 2007;19:24-32.
104. Kawai T, Akira S. TLR signaling. Cell Death Differ 2006;13:816-25.
105. Jilling T, Simon D, Lu J, et al. The roles of bacteria and TLR4 in rat and murine models of necrotizing enterocolitis. J Immunol 2006;177: 3273-82.
106. Leaphart CL, Cavallo J, Gribar SC, et al. A critical role for TLR4 in the pathogenesis of necrotizing enterocolitis by modulating intestinal injury and repair. J Immunol 2007;179:4808-20.
107. Reynolds JM, Martinez GJ, Chung Y, et al. Tolllike receptor 4 signaling in T cells promotes autoimmune inflammation. Proc Natl Acad Sci USA 2012;109:13064-9.
108. Medzhitov R, Preston-Hurlburt P, Kopp E, et al. MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. Mol Cell 1998;2:253-8.
109. Fukata M, Michelsen KS, Eri R, et al. Toll-like receptor-4 is required for intestinal response to epithelial injury and limiting bacterial translocation in a murine model of acute colitis. Am J Physiol Gastrointest Liver Physiol 2005;288: G1055-65.
110. Zhang Y, Chen H, Yang L. Toll-like receptor 4 participates in gastric mucosal protection through Cox-2 and PGE2. Dig Liver Dis 2010; 42:472-6.
111. Lai XY, Egan LJ. Suppression of radiationinduced DNA double-strand break repair by MyD88 is accompanied by apoptosis and crypt loss in mouse colon. Oncogenesis 2013;2:e62.
112. Egan LJ, Eckmann L, Greten FR, et al. IkappaBkinasebeta-dependent NF-kappaB activation provides radioprotection to the intestinal epithelium. Proc Natl Acad Sci USA 2004;101: 2452-7.
113. Riehl T, Cohn S, Tessner T, et al. Lipopolysaccharide is radioprotective in the mouse intestine through a prostaglandin-mediated mechanism. Gastroenterology 2000;118:1106-16.
114. Gibson DL, Ma C, Bergstrom KS, et al. MyD88 signalling plays a critical role in host defence by controlling pathogen burden and promoting epithelial cell homeostasis during Citrobacter rodentium-induced colitis. Cell Microbiol 2008; 10:618-31.
115. Lebeis SL, Bommarius B, Parkos CA, et al. TLR signaling mediated by MyD88 is required for a protective innate immune response by neutrophils to Citrobacter rodentium. J Immunol 2007; 179:566-77.
116. Gribar SC, Sodhi CP, Richardson WM, et al. Reciprocal expression and signaling of TLR4 and TLR9 in the pathogenesis and treatment of necrotizing enterocolitis. J Immunol 2009;182: 636-46.
117. Kaczmarek A, Brinkman BM, Heyndrickx L, et al. Severity of doxorubicin-induced small intestinal mucositis is regulated by the TLR-2 and TLR-9 pathways. J Pathol 2012;226: 598-608.
118. Logan RM, Gibson RJ, Bowen JM, et al. Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis. Cancer Chemother Pharmacol 2008; 62:33-41.
119. Gibson RJ, Keefe DM, Thompson FM, et al. Effect of interleukin-11 on ameliorating intestinal damage after methotrexate treatment of breast cancer in rats. Dig Dis Sci 2002;47: 2751-7.
120. Cuschieri J, Billigren J, Maier RV. Endotoxin tolerance attenuates LPS-induced TLR4 mobilization to lipid rafts: a condition reversed by PKC activation. J Leukoc Biol 2006; 80:1289-97.
121. Peng Y, Sigua CA, Rideout D, et al. Deletion of toll-like receptor-4 downregulates protein kinase C-zeta and attenuates liver injury in experimental pancreatitis. Surgery 2008;143:679-85.
122. Eun CS, Han DS, Lee SH, et al. Attenuation of colonic inflammation by PPARgamma in intestinal epithelial cells: effect on Toll-like receptor pathway. Dig Dis Sci 2006;51:693-7.
123. Molnar K, Vannay A, Szebeni B, et al. Intestinal alkaline phosphatase in the colonic mucosa of children with inflammatory bowel disease. World J Gastroenterol 2012;18:3254-9.